MorphoSys (ETR:MOR) Given a €150.00 Price Target by Berenberg Bank Analysts

Berenberg Bank set a €150.00 ($174.42) target price on MorphoSys (ETR:MOR) in a research report released on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently weighed in on the stock. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Wednesday, August 7th. HSBC set a €81.00 ($94.19) price objective on shares of MorphoSys and gave the stock a sell rating in a research note on Friday, August 16th. Deutsche Bank set a €133.00 ($154.65) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Thursday, August 8th. Independent Research set a €116.00 ($134.88) price objective on shares of MorphoSys and gave the stock a neutral rating in a research note on Tuesday, August 13th. Finally, Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the stock a neutral rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of €119.67 ($139.15).

Shares of MorphoSys stock opened at €106.10 ($123.37) on Monday. The company has a current ratio of 7.62, a quick ratio of 7.40 and a debt-to-equity ratio of 8.61. The stock has a market capitalization of $3.35 billion and a price-to-earnings ratio of -80.32. MorphoSys has a 1-year low of €76.45 ($88.90) and a 1-year high of €114.70 ($133.37). The firm’s 50-day moving average price is €107.51 and its two-hundred day moving average price is €93.29.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.